Library.

“The diabetes drug metformin can suppress HIV replication, keep the virus dormant, and enable long-term remission without the need for daily antiretroviral therapy.”

This claim dramatically overstates the evidence. While metformin shows some ability to modulate HIV biology in laboratory and animal studies, no clinical evidence supports the assertion that it can enable long-term remission without daily antiretroviral therapy. Multiple peer-reviewed studies actually show metformin can increase HIV transcription and reactivate latent virus. All human studies tested metformin only as an add-on to ART, not as a replacement. The claim conflates early-stage, preclinical findings with established clinical capability.

“Metformin can keep HIV in a dormant state by blocking the DDIT4 gene.”

This claim is not supported by the available evidence. No peer-reviewed study links metformin's effects on HIV latency specifically to "blocking the DDIT4 gene." The primary literature describes metformin acting through AMPK/mTOR/mitochondrial pathways with mixed antiviral and proviral effects. Critically, DDIT4 is a negative regulator of mTORC1, so blocking it would increase mTOR activity—the opposite direction needed to promote HIV dormancy. The claim appears to stitch together unrelated biological facts into an unsupported causal chain.